Tuesday 6 March 2012

Peritoneal Mesothelioma

Peritoneal Mesothelioma

Peritoneal mesothelioma is the second-most common type of mesothelioma and accounts for 10 to 20 percent of all mesothelioma cases. The cancer develops in the abdomen over a course of decades after asbestos fibers are inhaled or ingested. Modern diagnostic tests are used to detect peritoneal mesothelioma. Although the disease is usually diagnosed in the later stages of development, treatment options are available.
Some patients may be good candidates for curative treatments such as surgery, while others may elect for palliative measures alone. Overall prognosis for peritoneal mesothelioma patients is less than one year. However, life expectancy can increase with effective treatment. Working with a mesothelioma specialist helps patients receive the best possible care for their cancer, which could have a significant impact on a patient's prognosis.----------------------------------------------------------------------------------------------------------------

Peritoneal Mesothelioma Prognosis

Some studies have found that men live an average of seven months after being diagnosed with peritoneal mesothelioma, with some patients living up to 100 months. Women, on the other hand, generally live for about nine months after diagnosis, with some living up to 49 months. Prognosis is generally better in patients whose mesothelioma is diagnosed early and whose symptoms are less severe. The cell structure of the tumors can also play a part in life expectancy, as well as treatments selected.